GlassScriptPhysician profile
Tera R Thompson
NPI 1710307848
$2,816.85
in general payments reported to CMS, 2019-2025
21 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $872 · 2022: $308 · 2023: $943 · 2024: $249 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.01 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $659.91 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $283.37 | 2021-2023 | |
| Abbott Laboratories | $258.27 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Insulinx |
| Merz North America, INC. | $247.30 | 2022-2025 | |
| Novo Nordisk INC | $233.55 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $220.76 | 2021 | |
| Amgen INC. | $205.68 | 2021-2024 | Repatha, Otezla |
| Dexcom, INC. | $166.12 | 2022-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $162.09 | 2021-2022 | |
| Lilly USA, LLC | $84.08 | 2021-2024 | Zepbound, Mounjaro |
| Pfizer INC. | $59.17 | 2021-2024 | |
| Abbvie INC. | $49.55 | 2021-2025 | |
| Galderma Laboratories, L.P. | $45.47 | 2022 | |
| Alkermes, INC. | $23.41 | 2022 | |
| Nestle Healthcare Nutrition INC. | $21.48 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $18.34 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.10 | 2022 | |
| Exact Sciences Corporation | $16.72 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $15.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.87 | 2021 | |
| Merck Sharp & Dohme LLC | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tera Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.